Prevention & care

Sjögren disease: dryness, wider autoimmune effects, antibody limitations, dental care, and systemic-treatment evidence

6 sources · Latest source check 2026-10-09 UTC

On this page

Sjögren disease is an autoimmune condition that commonly affects the glands producing tears and saliva. Dry eyes and dry mouth are prominent, but fatigue, pain and involvement of other organs can also occur. It may occur alone or alongside another autoimmune disease.[1]

Gland symptoms and wider manifestations differ

Gland symptoms and wider manifestations differ
Area	Examples and consequences
Tears	Dryness and irritation can affect eye comfort and function.[1]
Saliva	Dry mouth can affect speaking, swallowing and oral health.[1]
Wider symptoms	Fatigue, joint symptoms and other organ involvement can occur.[1]
Coexisting disease	Sjögren can occur with rheumatoid arthritis or lupus.[1]

Dryness is a symptom; Sjögren is a clinical disease assessment

NIAMS assesses gland function and an autoimmune process, rather than one symptom or blood result. Drying medicines and other causes also matter. Similar dryness in different people does not establish the same underlying disease.[2]

Blood tests, gland function and selected tissue tests provide different information

The ACR describes antibody tests, eye and salivary assessment, and sometimes salivary-gland biopsy. Some people with Sjögren lack the commonly measured antibodies. A negative antibody result therefore does not by itself exclude the disease. Conversely, an antibody result requires interpretation alongside the clinical findings; tests are parts of the assessment rather than interchangeable confirmations.[3]

Replacing tears and retaining tears are different strategies

NIAMS describes lubricants, selected anti-inflammatory eye treatments and tear-drainage plugs. Plugs retain available tears by reducing drainage; they do not create new glands. Ointments can blur vision. These approaches address different aspects of dryness.[2]

Saliva replacement and saliva stimulation also differ

NIAMS distinguishes saliva substitutes from medicines that stimulate secretion. Treating an oral fungal infection is another separate objective. A dryness product does not establish that an infection is present, and antimicrobial treatment does not by itself replace the saliva needed for comfort and oral protection.[2]

Eye and dental care address consequences as well as symptoms

The ACR explains that reduced tears and saliva can contribute to corneal problems, dental decay and oral infections. Regular eye and dental assessment can therefore matter even when discomfort seems manageable. A short-term comfort improvement does not establish that all risks to the eye surface or teeth have disappeared.[3]

Practical measures support dryness management

The NHS discusses oral hygiene, fluoride toothpaste, regular dental checks and sugar-free gum, alongside selected prescribed options and eye care. These measures have different purposes: stimulating saliva, protecting teeth and relieving irritation. They are supportive care, rather than proof that the autoimmune process has been removed.[4]

Treatment follows the organs and activity involved

The NHS distinguishes symptom-focused care from selected medicines used for other manifestations. Someone whose main difficulty is dryness and someone with important systemic involvement may have different treatment aims. A universal “immune boosting” or “immune suppressing” label is too broad to describe these decisions; the particular disease process and outcome matter.[4]

The BSR guideline separates secretion care, damage prevention and systemic activity

“Disease” and “syndrome” are names used for this condition. The British Society for Rheumatology guideline was published online in April 2024, with a 2025 journal issue. It addresses adults and, where appropriate, children. Its approach includes conserving, replacing or stimulating secretions, preventing damage and addressing systemic disease, pain, fatigue, function and quality of life.[5]

Its executive recommendations consider hydroxychloroquine for selected fatigue/systemic contexts and advise against routinely offering systemic steroids for the disease as a whole. These are conditional clinical judgments, not evidence that every person should receive either medicine. Only the original abstract, introduction and selected executive recommendations were inspected here; full evidence-table appraisal remains outstanding.[5]

JOQUER tested a specific symptom outcome over twenty-four weeks

Gottenberg and colleagues’ 2014 trial randomized 120 people with primary Sjögren disease to hydroxychloroquine or placebo. The primary outcome was at least 30% improvement in two of three symptom scales: dryness, pain and fatigue. At twenty-four weeks, 17.9% versus 17.2% met it; the odds ratio was 1.01, with a 95% confidence interval of 0.37–2.78.[6]

That result did not demonstrate benefit on the specified outcome. The interval does not prove equivalence for every organ question. After twenty-four weeks both groups received hydroxychloroquine, ending the placebo comparison. Full funding and long-term harms were not appraised. The trial and guideline address different questions.[6]

A higher lymphoma risk is different from an inevitable outcome

NIAMS notes an increased lymphoma risk while emphasizing that it remains low. That distinction matters: a higher relative risk does not mean that most people develop lymphoma. A single percentage without its population and follow-up period would oversimplify the prognosis.[1]

Long-term support and a cure are different claims

The NHS describes a long-term condition with treatment aimed at easing symptoms. Support can include managing fatigue and the effects on ordinary life. A product that briefly improves dryness has not thereby demonstrated durable disease modification, protection of all organs or a cure.[4]

Evidence & uncertainty

Dryness alone does not establish Sjögren disease, and no single test settles every diagnosis. Care for dryness, prevention of dental or eye damage and treatment of systemic disease answer different questions. A randomized hydroxychloroquine trial did not improve its primary dryness/pain/fatigue outcome at twenty-four weeks; this does not resolve every selected systemic-treatment question.[2][6][5]

Selected-source overview · Independent review pending

Published questions

Do Sjögren disease and Sjögren syndrome name completely different illnesses?

Selected-source overview · Independent review pending. Read the evidence context.

Both names are used for this condition.[5]

Evidence behind this answer

British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease
professional guideline · 2024
Original indexed abstract/introduction and selected original executive recommendations inspected; full evidence appraisal incomplete · April 2024 online / 2025 issue: main guideline scope and selected executive hydroxychloroquine/steroid recommendations